Lowe syndrome, also known as oculocerebrorenal syndrome, is caused by mutations in the X chromosomeencoded OCRL gene. The Lowe syndrome, also known as oculocerebrorenal syndrome, is an X chromosome-linked disorder that is characterized by severe mental retardation, areflexia, hypotonia, a variety of eye abnormalities, and a renal Fanconi syndrome with impaired reabsorption of glucose, amino acids, phosphate urate, and bicarbonate. Patients have renal tubular acidosis, metabolic bone disease, and growth failure. The eye abnormalities include cataracts, decreased acuity, and glaucoma (1, 2). The protean manifestations of the disorder suggest that the defect involves a gene that mediates a critical cellular function shared by many cell types and organs. In 1992 Nussbaum and coworkers (3) identified a candidate Lowe syndrome gene by positional cloning of X chromosome breakpoints in two affected females. The predicted protein, designated OCRL, was found to be 51% identical over a span of 744 aa to inositol polyphosphate 5-phosphatase type II (5-phosphatase II) (4), an enzyme of the inositol phosphate signaling pathway that was originally isolated from human platelets (5) inositol polyphosphate 5-phosphatase type I (5-phosphatase I) (6-9). These soluble inositol phosphates are involved in calcium signaling reactions, and thus the 5-phosphatase enzymes function in signal-terminating reactions (10). Recently it has been shown that 5-phosphatase II also hydrolyzes the 5-phosphate from the phospholipid phosphatidylinositol 4,5-bisphosphate [Ptdlns(4, 5 )P2] (9, 11). We now report that OCRL, the protein encoded by the Lowe syndrome locus, also is a Ptdlns(4,5)P2 5-phosphatase. OCRL also hydrolyzes the other 5-phosphatase substrates, albeit less well than the other isoenzymes. Sph I site is located (5'-CCTCATTGGCATCAGGCATGC-3'). This PCR product encodes amino acids Met264 to Met506 after digestion with Sph I and BamHI. The second cDNA was constructed by PCR using the same antisense primer and a sense primer that is identical to that shown above with insertion of nucleotides encoding seven histidine residues following nt 806-808. (5'-CGGGATCCAAAATGCACCAC-CACCACCACCACCACCTTCCACGTGAAAAAGAAG-C-3'). The two PCR products were digested with BamHI/Sph I and subcloned into the same region of ps.OCRLB-1 to replace the original aa 1-506 of the OCRLB-1 cDNA. The resulting plasmids ps.OCRL4 and ps.OCRL5 (with histidine tag) were sequenced throughout the PCR region to exclude mutations (Sequenase 2.0; United States Biochemical). ps.OCRL4 and ps.OCRL5 were subsequently subcloned between the BamHI and Xba I sites of the baculovirus transfer vector pVL1393 (PharMingen).
ability of OCRL to catalyze the three reactions is different from that of 5-phosphatase II and from that of another 5-phosphatase isoenzyme from platelets, 5-phosphatase I. The recombinant OCRL protein hydrolyzes the phospholipid substrate 10-to 30-fold better than 5-phosphatase II, and 5-phosphatase I does not cleave the lipid at all. We also show that OCRL functions as a phosphatidylinositol 4,5-bisphosphate 5-phosphatase in OCRL-expressing 59 cells. These results suggest that OCRL is mainly a lipid phosphatase that may control cellular levels of a critical metabolite, phosphatidylinositol 4,5-bisphosphate. Deficiency of this enzyme apparently causes the protean manifestations of Lowe syndrome.
Lowe syndrome, also known as oculocerebrorenal syndrome, is an X chromosome-linked disorder that is characterized by severe mental retardation, areflexia, hypotonia, a variety of eye abnormalities, and a renal Fanconi syndrome with impaired reabsorption of glucose, amino acids, phosphate urate, and bicarbonate. Patients have renal tubular acidosis, metabolic bone disease, and growth failure. The eye abnormalities include cataracts, decreased acuity, and glaucoma (1, 2) . The protean manifestations of the disorder suggest that the defect involves a gene that mediates a critical cellular function shared by many cell types and organs. In 1992 Nussbaum and coworkers (3) identified a candidate Lowe syndrome gene by positional cloning of X chromosome breakpoints in two affected females. The predicted protein, designated OCRL, was found to be 51% identical over a span of 744 aa to inositol polyphosphate 5-phosphatase type II (5-phosphatase II) (4) , an enzyme of the inositol phosphate signaling pathway that was originally isolated from human platelets (5) and that catalyzes the hydrolysis of the 5-position phosphate from both inositol 1,4,5-trisphosphate [Ins(1,4,5)P3] and inositol 1,3,4,5-tetrakisphosphate [Ins(1,3,4,5)P4]. These same substrates are also utilized by a more distantly related platelet isoenzyme
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inositol polyphosphate 5-phosphatase type I (5-phosphatase I) (6) (7) (8) (9) . These soluble inositol phosphates are involved in calcium signaling reactions, and thus the 5-phosphatase enzymes function in signal-terminating reactions (10 Baculovirus Expression and Labeling. Recombinant baculoviruses containing either 5-phosphatase II cDNA (9), ps.OCRL4, ps.OCRL5, or a control construct encoding protein-tyrosine phosphatase Meg-01 (13) were grown in TNM-FH medium with 10% heat-inactivated fetal bovine serum and 100 ,g of gentamicin per ml (14) .
For studies on 32P-labeling of Sf9 cell phospholipids, 3 x 106 Sf9 cells were infected with baculovirus encoding the abovementioned constructs. Three days after infection the cells were harvested from 60-mm dishes and resuspended in 450 ,ul of phosphate-free Grace's insect medium containing 1 mCi (37 MBq) of [32P]phosphate at room temperature. Samples of 100 ,lI were taken after various times and added to 100 pul of 1 M HCI. 32P-labeled phosphatidylinositols were further extracted with chloroform/methanol, separated by TLC, and measured as described (15) . as substrate was as described (5, 6) . Assay of 5-phosphatase activity using [3H]PtdIns(4,5)P2 was as described (7) except that PtdIns(4,5)P2 was at a concentration of 50 ,uM and that the assay was conducted at 37°C. The products formed from incubation of OCRL protein with Ins(1,4,5)P3 and Ins(1,3,4,5)P4 were separated by HPLC on an Adsorbosphere SAX column equilibrated in 20 mM NH4H2PO4 at pH 3.5. Products were eluted with a linear gradient from 0 to 0.75 M NH4H2PO4 over 100 min, 0.5-ml fractions were collected, and radioactivity was measured in a liquid scintillation counter.
We prepared rabbit polyclonal antibodies to a peptide that 
RESULTS
The finding that the protein mutated in Lowe syndrome, OCRL, is homologous to 5-phosphatase II suggested that OCRL might be an isoenzyme of 5-phosphatase. We initially assayed extracts of fibroblast cell lines from patients with Lowe syndrome for 5-phosphatase activity using Ins(1,4,5)P3 and found no abnormalities. Phosphatidylinositol turnover and levels of inositol phosphates were also measured in fibroblasts from patients, and no differences from control fibroblasts were found (data not shown).
We therefore turned to a direct approach to define the function of the OCRL protein. An OCRL cDNA expression vector was constructed so that translation started at Met264.
This choice was based on our previous experience with the homologous platelet 5-phosphatase II. The 5-phosphatase II cDNA encodes a protein of 942 aa but the amino-terminal sequence of the isolated platelet protein begins at aa 270. This finding suggests that the platelet enzyme may be processed from a larger precursor. A construct of the 5-phosphatase II (aa 250-942) expressed in Sf9 cells yielded a recombinant protein with an enzyme activity that was identical to that of the protein isolated from platelets (9) . Also, the homology between OCRL and 5-phosphatase II begins at the region of the amino terminus of the mature platelet enzyme. The long open reading frame 5' of this region has no homology to 5-phosphatase II. Because the conserved sequence in OCRL coincided with the mature processed form of platelet 5-phosphatase II, we assumed that the OCRL protein might also be processed, and therefore we engineered the expression construct to begin at the same region. In initial experiments we infected Sf9 cells with recombinant baculovirus harboring ps.OCRL4 and ps.OCRL5. After 3 days of infection, cells were harvested and disrupted by sonication and extracts of the ps.OCRL5-infected cells were affinity purified. The crude extracts and purified protein were run in SDS/polyacrylamide gels, transferred to nitrocellulose membranes, stained with Coomassie Blue, and immunoblotted with anti-peptide antibodies. The affinity-purified OCRL migrated as a single band (Fig. 1, lane 4 (Table 1) .
We also determined that OCRL functions as a Ptdlns(4,5)P2 5-phosphatase in Sf9 cells infected with either ps.OCRL4 or a baculoviral construct encoding a control protein, Meg-01. We measured the turnover of cellular phospholipid after 3 days of infection by pulse-labeling with [32P]phosphate for 1-30 min (Fig. 4) . In Sf9 cells expressing the control protein (as well as in uninfected Sf9 cells; data not shown) more 32pwas incorporated into PtdIns(4,5)P2 than into PtdIns(4)P at all times. In contrast, cells expressing OCRL had a decreased incorporation of 32p into Ptdlns(4,5)P2, due to hydrolysis of the 5-phosphate group with a relative increased incorporation into Ptdlns(4)P. The incorporation of 32p into total cell phospholipids was the same in both infections (14 cpm/min per nmol of phospholipid for the control and 11 cpm/min per nmol of phospholipid for OCRL).
DISCUSSION
Lowe syndrome is the first human disorder described resulting from a defect in the inositol phosphate signaling pathway. It (17) (18) (19) (20) (21) , secretion (22) , protein kinase C action (23) (24) (25) , and ATPases (26, 27) , one or more of which could be important in the pathogenesis of Lowe syndrome. All whether the full-length OCRL protein will have the same properties as those reported here awaits further study.
